INSTITUTIONAL BIOSAFETY COMMITTEE

UNIVERSITY of WASHINGTON

Meeting Minutes

Date: Wednesday, April 17, 2019
Time: 10:00 AM – 12:00 PM

Location: Health Sciences Building, Room E202

Members Present:

1. H.D. "Toby" Bradshaw, Biology *(Plant Expert)*
2. Richard Grant, Washington National Primate Research Center
3. Garry Hamilton (*Community Member*)
4. Kevin Hybiske, Allergy and Infectious Diseases
5. David Koelle, Allergy and Infectious Diseases
6. Stephen Libby, Laboratory Medicine (*IBC Chair*)
7. Scott Meschke, Environmental & Occupational Health Sciences
8. Jason Smith, Microbiology (*IBC Vice Chair*)
9. Eric Stefansson, Environmental Health & Safety (*Biosafety Officer, Animal Containment Expert*)
10. Paul Swenson, Seattle-King Co. Dept. of Public Health (*Community Member*)

Commonly Used Abbreviations
IBC: Institutional Biosafety Committee
BSO: Biological Safety Officer
BUA: Biological Use Authorization
BSL: biosafety level
PI: Principal Investigator
IACUC: Institutional Animal Care and Use Committee
NIH: National Institutes of Health
DURC: Dual Use Research of Concern
SOP: standard operating procedure

1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chair called the meeting to order at 10:03 a.m. A quorum was present. A new ad hoc reviewer was introduced.

2. **REMINDER:** The IBC Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.

3. **APPROVAL OF MINUTES:**
   - The IBC Chair sought a motion to approve the minutes from the March 20, 2019 meeting.
   - A member made a motion to approve the March 20, 2019 minutes. Another member seconded the motion.
   - The committee voted unanimously to approve the March 20, 2019 meeting minutes. There was one abstention from a member who was not present at the March IBC meeting.

4. **OLD BUSINESS:**
   - At the July 2018 meeting, Dr. Patel's BUA was approved pending a lab inspection. This is still pending.
   - At the October 2018 meeting, Dr. Stuber's BUA was approved pending a lab inspection and room changes to the BUA letter. This is still pending.
   - At the November 2018 meeting, Dr. Bornfeldt's BUA was approved pending additions to the BUA letter. This is still pending.
   - At the November 2018 meeting, Dr. Steinmetz's BUA was approved pending a successful lab inspection. This has been completed, and the BUA letter has been sent out.
   - At the January 2019 meeting, Dr. Noss's BUA was approved pending verification of third generation lentiviral vectors. This has been completed, and the BUA letter has been sent out.
   - At the February 2019 meeting, Dr. Berg's BUA was approved pending correction of deficiencies identified in a lab inspection. This has been completed, and the BUA letter has been sent out.
   - At the February 2019 meeting, Dr. Liao's BUA was approved pending a lab inspection and changes to the BUA. This is still pending.
   - At the February 2019 meeting, Dr. Lieber's BUA was approved pending a lab inspection and changes to the BUA. This has been completed, and the BUA letter has been sent out.
   - At the February 2019 meeting, Dr. Nahmani's BUA was approved pending a lab inspection and verification of third generation lentiviral vectors. This is still pending.
   - At the March 2019 meeting, Dr. Bajjalieh's BUA was approved pending additional information to the BUA. This is still pending.
   - At the March 2019 meeting, Dr. Fang's BUA was approved pending edits to the IACUC submission. This has been completed, and the BUA letter has been sent out.
   - At the March 2019 meeting, Dr. Fuller's BUAs were approved pending changes to the BUA. This has been completed, and the BUA letters have been sent out.
   - At the March 2019 meeting, Dr. Giacani's BUA was approved pending a change the the BUA letter. This has been completed, and the BUA letter has been sent out.
   - At the March 2019 meeting, Dr. Hladik's BUA was approved pending changes to the BUA application and a successful lab inspection. This is still pending.
   - At the March 2019 meeting, Dr. Kavanagh's BUA was approved pending a successful lab inspection, completion of training, and changes to the BUA letter. This has been completed, and the BUA letter has been sent out.

- At the March 2019 meeting, Dr. Merz's BUA was approved pending a successful lab inspection. This has been completed, and the BUA letter has been sent out.
- At the March 2019 meeting, Dr. Moreno's BUA was approved pending a successful lab inspection and training completion. This is still pending.
- At the March 2019 meeting, Dr. Neumaier's BUA was approved pending IACUC submission. This has been completed, and the BUA letter has been sent out.
- At the March 2019 meeting, Dr. Woodrow's BUA was approved pending submission of the IACUC protocol. This has been completed, and the BUA letter has been sent out.

5. **BIOSAFETY OFFICER (BSO) REPORT***:* The Biosafety Officer Report includes (1) projects involving recombinant or synthetic nucleic acids covered under section III-E and III-F of the *NIH Guidelines,* (2) proposals involving non-recombinant biohazardous agents requiring BSL-1 and BSL-2 containment, and (3) administrative updates, such as room additions.

   a. Biosafety Officer Report
      - Dr. King's BUA *King Lab Research* added the Pathology Flow Cytometry Core Facility.
      - Dr. Gottlieb's BUA *Antiretroviral Therapy for HIV-2 Infection In Senegal* added Human T-lymphotropic virus types 1 and 2.
      - Dr. Salipante's BUA *Next-generation sequencing for clinical translation* added the Pathology Flor Cytometry Core Facility.
      - Dr. Law was approved for a new BUA, *Human neural stem cells and hypothermia in a rat model of HIE.* This research uses human blood, tissue, body fluids, and cell lines in mice.
      - Dr. Gale's BUA *The Host Response to Virus Infection* added a non-recombinant Hepatitis D virus for in vitro use.
      - Dr. Disis's BUA *UW Gene and Cell Therapy Core* had a correction made to approved agents.
      - Dr. Raskind's BUA *Genetic Contributions to Dyslexia Gene Discovery in Neurogenetic Disorders; Spinocerebellar-Ataxia Type 14: Animal Models of Human Disease; Genetics of Autism; Genetics of Human Diseases* added a new lab space in the J-wing and removed their BB-wing lab location.
      - Dr. Xin's BUA *Studies on prostate homeostasis and prostate-related diseases* had a change to include in vitro work and lab spaces that were approved at the April 2018 IBC meeting.
      - Dr. Daggett renewed the BUA *Peptide-Based Diagnostics and Inhibitors for Amyloid Diseases.* This research uses human blood, tissue, body fluids, and cell lines and various BSL2 agents in vitro.
      - Dr. Cao's BUA *Predicting Therapy Response* added the use of NN143C for work with previously approved agents.
      - Dr. Yager's BUA *EbolaBox Disposable Protein Detection Test* added Mycobacterium tuberculosis H37Ra strain.
      - Dr. Patton renewed the BUA *Sexually Transmitted Disease Prevention – Primate Unit.* This research uses various BSL2 agents in vitro and in macaques.
      - Dr. Davis renewed the BUA *Molecular Analysis of Chromosome Segregation.* This research uses Baculovirus and non-pathogenic strains of E. coli in vitro.
      - Dr. Zheng renewed the BUA *Protein Structural Biology – Dr. Ning Zheng Lab.* This research uses Baculovirus, non-pathogenic strains of E. coli, recombinant or synthetic DNA/RNA (non-viral) - enhanced gene delivery methods, and human blood, tissue, body fluids, and cell lines in vitro.

- Dr. Posner's BUA *Point of Care HIV Viral Load Test* added the defective HIV-1 LAV/8E5 virus as a positive control in an HIV PCR test, to be purchased commercially.
- Dr. Davis' BUA *The cellular and molecular mechanism of cardiac wound healing and fibrotic remodeling* added uses of iPSC's in rats.
- Dr. Barker-Haliski renewed the BUA *Evaluating the anticonvulsant and disease modifying potential of investigational anticonvulsant drugs in a mouse model of infection induced seizures.* This research uses Theiler's murine encephalomyelitis (TMEV) in mice and in vitro.
- Dr. Bammler renewed the BUA *Generating data for large-scale molecular epidemiology studies using genotyping capabilities and gene expression profiling.* This research uses human and non-human primate blood, tissue, body fluids, and cell lines in vitro.
- Dr. Nakamura was approved for a new BUA, *NR2E3 Signaling to treat inherited retinal disease.* This research uses recombinant or synthetic DNA/RNA (non-viral) - enhanced gene delivery methods and human blood, tissue, body fluids, cell lines in vitro.
- The IBC Chair sought a motion to approve this month's Biosafety Officer Report.
- A member made a motion to approve this month's Biosafety Officer Report. Another member seconded the motion.
- The Committee unanimously voted to approve this month's Biosafety Officer Report. There was one abstention from a member who was not present during the entire report out.

6. DURC REPORT:

- Dr. Gross's project *Muscle paralysis and bone cell function* received approval for continued use of Botulinum neurotoxin. Botulinum Toxin A is used to induce transient muscle paralysis and explore how this paralysis precipitates rapid bone resorption in adjacent bone, how it augments bone formation and distant sites (both in mice), and how it can inhibit heterotopic ossification in the muscle in which it is injected (in rabbits). The group does not modify the agent in any manner.

7. INDIVIDUAL PROJECT REVIEWS

a. Brockerhoff, Susan, renewal, *Photoreceptor Mutations in Zebrafish*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This project creates transgenic zebrafish with a variety of metabolic genes (no known oncogenes) and reporters with the goal of understanding signaling and regulatory mechanisms with cone cells of the zebrafish retina.
- The lab was inspected and no deficiencies were identified.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Brockerhoff.
- The Committee voted unanimously to approve the draft BUA for Dr. Brockerhoff.

b. Disteche, Christine, renewal, *Molecular studies of sex chromosome aneuploidy*

- The assigned IBC Secondary Reviewer presented the Primary Review.

- This project utilizes cultured human cells, human embryonic stem cells, and induced pluripotent stem cells to evaluate the molecular consequences of an abnormal number of X or Y chromosomes, focusing on two common disorders: Klinefelter (XXY) and Turner (X) syndromes.
- The greatest risk to lab personnel, as stated by the PI, is in the culturing of human embryonic stem cells and induced pluripotent stem cells.
- The lab was inspected and no deficiencies were identified.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Secondary Reviewer made a motion to approve the draft BUA for Dr. Disteche.
- The Committee voted unanimously to approve the draft BUA for Dr. Disteche.

c. Giachelli, Cecilia M., renewal, *Engineering Osteoclasts to Prevent Medication-Related Osteonecrosis of the Jaw*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This lab uses exosomes or engineered cell lines for potential treatment of medication-related jaw bone osteonecrosis. Work includes use of 3rd generation lentiviral vectors, human and mouse cells, and liposome delivery of siRNA.
- Lentiviruses present the greatest biohazard risk to lab personnel.
- A lab inspection still needs to be completed.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Giachelli pending a successful lab inspection.
- The Committee voted unanimously to approve the draft BUA for Dr. Giachelli pending a successful lab inspection.

d. Gottlieb, Geoffrey, renewal, *Antiretroviral Therapy for HIV-2 Infection In Senegal*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This project tries to determine the efficacy of antiretroviral drugs in HIV-2-infected individuals and to characterize the mechanisms by which HIV-2 evolves resistance to these inhibitors.
- The greatest biohazard risk to lab personnel is work with HIV-1, HIV-2, SIV, HTLV-1, and HTLV-2.
- As a result of committee discussion, recombinant DNA work with plasmids will be listed on the BUA letter at BSL2.
- The lab was inspected and no deficiencies were identified.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Gottlieb pending the addition to the BUA letter.
- The Committee voted unanimously to approve the draft BUA for Dr. Gottlieb pending the addition to the BUA letter.

e. Harwood, Caroline, renewal, *Harwood Research Projects*

- The assigned IBC Primary Reviewer presented the Primary Review.

- This lab studies regulation, production, interactions, and survival of various recombinant risk group 1 and 2 organisms, including Acinetobacter baumannii and Pseudomonas aeruginosa.
- The lab was inspected and no deficiencies were identified.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Harwood.
- The Committee voted unanimously to approve the draft BUA for Dr. Harwood.

f. Jiao, Alex, renewal, *Expansion and preservation of human primary urine progenitor cells*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This project uses human blood cells with a commercial product, CytoTune, containing recombinant Sendai viral vectors that deliver and express the genes needed for reprogramming somatic cells to make induced pluripotent stem cells.
- Work with human blood and Sendai virus pose the greatest risk to lab personnel.
- A lab inspection still needs to be completed.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Jiao pending a successful lab inspection.
- The Committee voted unanimously to approve the draft BUA for Dr. Jiao pending a successful lab inspection.

g. Kwon, Young, renewal, *Regulation of growth and wasting*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This research uses lentiviral vectors to deliver GFP-alpha-arrestin fusion proteins to human cells and Drosophila to look for new mechanisms of organ growth and wasting.
- 1st or 2nd generation lentiviral vectors and work with human cells present the greatest risk to lab personnel.
- The lab was inspected, and deficiencies identified are being corrected.
- All of the required trainings have been completed. – pending one lab person
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Kwon pending a successful lab inspection.
- The Committee voted unanimously to approve the draft BUA for Dr. Kwon pending a successful lab inspection.

h. Manicone, Anne, renewal, *MMPs in Repair and Immunity*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This lab focuses on how macrophage programming can regulate recruitment and clearance of leukocytes and promote wound repair of fibrosis. There is work with human blood and cells, viral vectors, and small animal modeling of lung disease.
- Work with live bacteria, such as Pseudomonas aeruginosa, present the greatest risk to lab personnel.
- The lab was inspected and no deficiencies were identified.
- All of the required trainings have been completed.

- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Manicone.
- The Committee voted unanimously to approve the draft BUA for Dr. Manicone.

i. Miller, Samual, change, *Role of the phoP Regulon and Salmonella Virulence/Regulation of Salmonella Invasion of Epithelia/SPi2*

- The assigned IBC Primary Reviewer presented the Primary Review.
- Wild type BCG and two recombinant mutants of Mycobacterium bovis BCG are being added to this lab's work. This research is to understand the molecular and genetic mechanisms of Gram-negative bacterial pathogens, especially Salmonella, to gain insights into disease causation for better treatment and prevention.
- The lab was inspected and no deficiencies were identified.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Miller.
- The Committee voted unanimously to approve the draft BUA for Dr. Miller.

j. Morrissey, Colm, new, *SLFN11 May be the Key to Identifying New Combination Treatments to Treat CRPC*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This research attempts to transduce prostate cancer cell lines with lentiviral vectors to knockdown expression of the SLFN11 gene in order to determine whether the response to chemotherapeutics will be altered.
- The lab was inspected and no deficiencies were identified.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Morrissey.
- The Committee voted unanimously to approve the draft BUA for Dr. Morrissey.

k. Mougous, Joseph, change, *Type VI secretion-dependent interbacterial interactions*

- The assigned IBC Primary Reviewer presented the Primary Review.
- Shigella and an E. coli shiga toxin mutant strain are being added to this research work. Recombinant strains will be engineered to express selectable markers (gentamycin and kanamycin) and surface-associated synthetic antigens. The strains will then be used in interbacterial competition experiments. Oral aminoglycosides are not recommended for treating Shigella infections, so no concerns exist for introducing these markers.
- The lab was recently inspected, so a new lab inspection was not required for this change.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Mougous.
- The Committee voted unanimously to approve the draft BUA for Dr. Mougous.

l. Roble, Gordon, new, *Training and Technique Development in Mouse Models*

- The assigned IBC Primary Reviewer presented the Primary Review.
- Fred Hutch Comparative Medicine will demonstrate the advantages of a 3T MRI system over their current 1T MRI system by providing a side by side comparison in mice with tumors. The mice being brought to UW for imaging with the 3T MRI will be infected with plasmid or recombinant viral vectors. Handling of mice and anesthesia will be performed by Fred Hutch staff. Imaging equipment will be operated by UW staff.
- A lab inspection is not required since this work is being done in a core facility on its own inspection cycle.
- All of the required trainings have been completed.
- The Fred Hutch IACUC protocol needs to be submitted to UW IACUC.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Roble.
- The Committee voted unanimously to approve the draft BUA for Dr. Roble.

m. Shao, Dan, new, *Subtrates Metabolism of Heart*

- The assigned IBC Secondary Reviewer presented the Primary Review.
- This project studies mitochondrial function and cell metabolism in normal and diseased hearts. Work includes genetic engineering of plasmids in non-pathogenic E. coli, culture of human and non-human primate cell lines, and use of viral vectors.
- The lab was inspected and no deficiencies were identified.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Secondary Reviewer made a motion to approve the draft BUA for Dr. Shao.
- The Committee voted unanimously to approve the draft BUA for Dr. Shao.

n. Smith, Jason G., renewal, *Antiviral Mechanisms of Defensins*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This research attempts to understand how defenses function in mucosal defense to alter viral and bacterial infection and pathogenesis. This involves work with recombinant viruses, viral vectors, pseudo viruses or virus-like particles, plasmids or bac DNA, enteroids, and non-human primate cell lines.
- A successful lab inspection is needed.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Smith pending a successful lab inspection and IACUC renewal submission.
- The Committee voted unanimously to approve the draft BUA for Dr. Smith pending a successful lab inspection and IACUC renewal submission. One member with a conflict of interest abstained from the vote.

o. Stevens, Kelly, renewal, *Liver Repair and Regeneration*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This lab uses viral vectors and plasmids to transduce human and rodent cells for their work with liver and heart regeneration.
- The lab was inspected and no deficiencies were identified.
- All of the required trainings have been completed.
- The draft BUA letter was shown.

- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Stevens.
- The Committee voted unanimously to approve the draft BUA for Dr. Stevens.

p. Sweet, Ian, renewal, *Islet Cell and Functional Analysis Core of Diabetes Endocrinology Research Center*

- The assigned IBC Primary Reviewer presented the Primary Review.
- The Islet Core provides pancreatic islet cells to investigators for diabetes and metabolic studies. This includes work with primary human and rodent cells and cell lines, animal cell lines, human embryonic stem cells, and transduction with adenoviral vectors. No transgenes are oncogenes.
- A lab inspection still needs to be completed.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Sweet pending a successful lab inspection.
- The Committee voted unanimously to approve the draft BUA for Dr. Sweet pending a successful lab inspection.

q. Van Voorhis, Wesley C., renewal, *1. Immune Response: Chagas 2. Biochemistry of Protein Prenylation 3. Plasmodium falciparum Protein Farnesyltransferase Inhibitors 4. Drugs for Toxoplasma and Cryptosporidium 5. Giardia 6. Shigella Inhibitors*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This lab studies potential therapeutic drugs for infections caused by risk group 1 and 2 parasites and bacteria, crystal structures of potential drug targets by cloning and expressing the protein, and test compounds against these organisms in vitro and in mouse and rat models.
- Work with risk group 2 organisms presents the greatest risk to lab personnel.
- The lab was inspected and no deficiencies were identified.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Van Voorhis.
- The Committee voted unanimously to approve the draft BUA for Dr. Van Voorhis.

r. von Moltke, Jakob, change, *Initiation of Type 2 Immune Responses*

- The assigned IBC Primary Reviewer presented the Primary Review.
- Use of Provtella copri in wildtype and transgenic mice will be added to this research. The lab will not be culturing P. copri in their own lab.
- The lab was inspected and no deficiencies were identified.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. von Moltke.
- The Committee voted unanimously to approve the draft BUA for Dr. von Moltke.

8. SUBCOMMITTEE REPORTS:

s. Konkle, Barbara, new, *Phase III, open-label, single-dose, multi-center multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene (AAV5-hFIXco-Padua, AMT-061) administered to adult subjects with severe or moderately severe hemophilia B*

- Two members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
- Delivery of a functional factor IX gene via a viral vector is a possible mechanism for gene delivery to care for Hemophilia B. Storage, preparation, and infusion of the drug product will take place at UW.
- Prolonged shedding of AAV may occur for one year or more, but is very unlikely to be infectious. The manufacturer does not recommend any containment or protection measures.
- The draft BUA letter was shown.
- A member made a motion to approve the draft BUA letter for Dr. Konkle. Another member seconded the motion.
- <u>The Committee voted unanimously to approve the draft BUA for Dr. Konkle.</u>

t. Konkle, Barbara, new, *Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100hFIX-Padua) in adult male participants with moderately severe hemophilia B (FIX:C<2%) (BeneGene-2)*

- Two members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
- Delivery of a functional factor IX gene via a viral vector is a possible mechanism for gene delivery to care for Hemophilia B. Storage, preparation, and infusion of the drug product will take place at UW.
- Prolonged shedding of AAV may occur for one year or more, but is very unlikely to be infectious. The manufacturer does not recommend any containment or protection measures.
- The draft BUA letter was shown.
- A member made a motion to approve the draft BUA letter for Dr. Konkle. Another member seconded the motion.
- <u>The Committee voted unanimously to approve the draft BUA for Dr. Konkle.</u>

u. JEV, WNV Review, new

- Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
- The subcommittee was asked if Japanese Encephalitis Virus (JEV) should be used at BSL3/ABSL3 for two projects in review. They were also asked to verify previous IBC rulings regarding work with West Nile Virus (WNV) at BSL/ABSL2 with 3 practices.
- The subcommittee found that high titer intranasal infection leads to the greatest animal shedding, but both PIs requesting to use JEV are not using this method. The IBC would have to reevaluate if either PI wants to use intranasal infection methods. There is minimal risk of aerosol infection.
- The subcommittee did verify that there have been three previous IBC rulings to maintain work with WNV at BSL/ABSL2 with 3 practices. There is no risk of aerosol transmission.

- The subcommittee stated that research with the SA-14-2 strain may be performed at BSL/ABSL2, and that research with the Nakayama strain may be performed in vitro only, at BSL2 with 3 practices, and without respiratory protection. They recommend considering work with additional JEV strains on a case by case basis and including specific language on each BUA letter regarding the type of strain in use.
- The JEV vaccine is required to be offered to lab workers. Husbandry staff are not required to be offered the vaccine.
- A member made a motion to approve the Subcommittee's recommendation.
- The Committee voted unanimously to approve the Subcommittee's recommendation.

10. FOR YOUR INFORMATION:

- The BSL3 Inactivation Subcommittee's proposed recommendations will be discussed at next IBC meeting on May 16.
- The committee shared about their experiences at the April 2019 Northwest Association for Biomedical Research (NWABR) Conference, where the IBC Chair and a biosafety officer presented.

11. ISSUES FROM THE FLOOR & PUBLIC COMMENTS:

There were no issues from the floor, and no public comments.

12. MEETING ADJOURNED AT APPROXIMATELY 11:59 A.M.